INAB's Business Model
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://in8bio.com |
| CEO (Chief Executive Officer) | Tai-Wei |
| Number of Employees | |
| IPO date | July 30, 2021 |
INAB Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 350 5th Avenue |
| City | New York City |
| State | NY |
| Phone | 646 600 6438 |
| Zip Code | 10118 |
| Other Identifiers | |
| CIK | 0001740279 |
| ISIN | US45674E2081 |
| CUSIP | 45674E208 |
| Open | 1.7 |
| Previous Close | 1.7 |
| Volume | 25.59 Thou. |
| Average Volume | 284.9 Thou. |
| Day’s Range | 1.665 – 1.75 |
| 52 Week Range | 1.17-8.25 |
| MA (50) | 1.9964 |
| MA (200) | 2.23884 |
| Market Cap | 7.83 Mil. |
| Shares Out. | 4.64 Mil. |
| Earnings Date | Mar 12, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
Industry Competitors for INAB
|
Company
|
PE Ratio | Market Cap |
|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
